[go: up one dir, main page]

WO2008112283A3 - Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment - Google Patents

Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment Download PDF

Info

Publication number
WO2008112283A3
WO2008112283A3 PCT/US2008/003346 US2008003346W WO2008112283A3 WO 2008112283 A3 WO2008112283 A3 WO 2008112283A3 US 2008003346 W US2008003346 W US 2008003346W WO 2008112283 A3 WO2008112283 A3 WO 2008112283A3
Authority
WO
WIPO (PCT)
Prior art keywords
predicting
prostate cancer
androgen
responsiveness
cancer treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/003346
Other languages
French (fr)
Other versions
WO2008112283A2 (en
Inventor
Chang Hee Kim
Xiaolin Wu
Jose Soto
David Munroe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2008112283A2 publication Critical patent/WO2008112283A2/en
Publication of WO2008112283A3 publication Critical patent/WO2008112283A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to methods of predicting responsiveness of prostate cancer patients to androgen ablation therapy by determining an androgen responsiveness microRNA expression profile of a tumor cell, and correlating the androgen responsiveness microRNA expression profile to the therapeutic treatment (androgen responsiveness).
PCT/US2008/003346 2007-03-12 2008-03-12 Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment Ceased WO2008112283A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90674207P 2007-03-12 2007-03-12
US60/906,742 2007-03-12

Publications (2)

Publication Number Publication Date
WO2008112283A2 WO2008112283A2 (en) 2008-09-18
WO2008112283A3 true WO2008112283A3 (en) 2009-03-26

Family

ID=39760294

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003346 Ceased WO2008112283A2 (en) 2007-03-12 2008-03-12 Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment

Country Status (1)

Country Link
WO (1) WO2008112283A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
WO2009080437A1 (en) * 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
WO2009108860A2 (en) * 2008-02-28 2009-09-03 The Ohio University Rasearch Foundation Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
GB2465088C (en) * 2008-10-30 2016-01-27 Caris Mpi Inc miRNA expression in the characterisation and classification of cancer
JP2012039876A (en) * 2008-12-26 2012-03-01 Univ Of Tokushima Prediction of effectiveness of preoperative chemoradiotherapy on rectal cancer using micro-rna
CA2762986C (en) * 2009-05-22 2018-03-06 Asuragen, Inc. Mirna biomarkers of prostate disease
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2011040613A1 (en) 2009-10-01 2011-04-07 独立行政法人国立がん研究センター Therapeutic agent for tumor
CN103237901B (en) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 For treating the biomarker of diagnosis
CA2795776A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
US9598734B2 (en) 2010-04-29 2017-03-21 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
JP5755849B2 (en) * 2010-07-06 2015-07-29 東レ株式会社 Composition or kit for determining sensitivity to adjuvant chemotherapy for gastric cancer
GB201014049D0 (en) * 2010-08-23 2010-10-06 Sistemic Uk Cell characterisation
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
WO2013090620A1 (en) 2011-12-13 2013-06-20 Genomedx Biosciences, Inc. Cancer diagnostics using non-coding transcripts
ES2945036T3 (en) 2012-08-16 2023-06-28 Veracyte Sd Inc Prognosis of prostate cancer using biomarkers
WO2014159443A1 (en) * 2013-03-14 2014-10-02 Genomedx Biosciences, Inc. Cancer biomarkers and classifiers and uses thereof
FI3198035T3 (en) 2014-09-26 2023-01-31 Methods for predicting drug responsiveness
CN105648050B (en) * 2015-04-09 2019-12-20 内蒙古农业大学 Method for rapidly identifying cashmere cycle development and molecular target and application thereof
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2018210695B2 (en) 2017-01-20 2024-07-18 The University Of British Columbia Molecular subtyping, prognosis, and treatment of bladder cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
JP2020513192A (en) * 2017-03-29 2020-05-07 中国医学科学院基礎医学研究所 Small RNA and its application in the prevention and / or treatment of fibroproliferative diseases and / or syndromes
EP3619320B1 (en) * 2017-05-03 2024-09-11 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Predictive response biomarkers to glucocorticosteroids
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
CN108130366B (en) * 2017-11-10 2021-02-19 中山大学 Method for constructing human miRNA sequencing library for high-throughput sequencing

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043548A1 (en) * 1999-01-21 2000-07-27 Board Of Regents Of The University Of Nebraska Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
EP1243653A2 (en) * 1996-09-06 2002-09-25 The Regents Of The University Of California E25a protein, methods for producing and use thereof
US6566130B1 (en) * 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
WO2005060661A2 (en) * 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
US20060064768A1 (en) * 2004-09-21 2006-03-23 The Regents Of The University Of California Murine Pten null prostate cancer model

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1243653A2 (en) * 1996-09-06 2002-09-25 The Regents Of The University Of California E25a protein, methods for producing and use thereof
WO2000043548A1 (en) * 1999-01-21 2000-07-27 Board Of Regents Of The University Of Nebraska Therapeutic and diagnostic applications of prostatic acid phosphatase in prostate cancer
US6566130B1 (en) * 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
WO2005060661A2 (en) * 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
US20060064768A1 (en) * 2004-09-21 2006-03-23 The Regents Of The University Of California Murine Pten null prostate cancer model

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BABAK T ET AL: "Probing microRNAs with microarrays: Tissue specificity and functional inference", RNA, COLD SPRING HARBOR LABORATORY PRESS, WOODBURY, NY, US, vol. 10, no. 11, 1 November 2004 (2004-11-01), pages 1813 - 1819, XP002403367, ISSN: 1355-8382 *
GRIFFITHS-JONES SAM ET AL: "miRBase: microRNA sequences, targets and gene nomenclature", NUCLEIC ACIDS RESEARCH, vol. 34, no. Sp. Iss. SI, January 2006 (2006-01-01), pages D140 - D144, XP002510809, ISSN: 0305-1048 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US7888035B2 (en) 2008-10-30 2011-02-15 Caris Mpi, Inc. Methods for assessing RNA patterns
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors

Also Published As

Publication number Publication date
WO2008112283A2 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2008112283A3 (en) Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
WO2012006584A3 (en) Therapeutic regimens for hedgehog-associated cancers
MX2009008132A (en) Combination therapy with angiogenesis inhibitors.
PL2252893T3 (en) Method for early determination of recurrence after therapy for prostate cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
PH12017501500A1 (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
WO2010077589A3 (en) Stat3 inhibitors and therapeutic methods using the same
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
EP2205076A4 (en) Combination therapy for the treatment of cancer using cox-2 inhibitors and dual inhibitors of egfr ýerbb1¨and her-2 ýerbb2¨
EP3106168A3 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
WO2011037643A3 (en) Compositions and methods for detecting and treating prostate carcinoma
EA201491701A1 (en) CANCER TREATMENT WITH TOR KINASE INHIBITORS
WO2011146568A8 (en) Predicting response to a her inhibitor
EP2373794A4 (en) Nectin-4 for target genes of cancer therapy and diagnosis
WO2013019945A3 (en) Method for selection of chemotherapeutic agents for adenocarcinoma cancer
EP2329044A4 (en) Prmt1 for target genes of cancer therapy and diagnosis
ZA202106392B (en) Therapeutic rna for prostate cancer
EP2147122A4 (en) ENZYMATIC TUMOR THERAPY
WO2010054397A3 (en) N-cadherin: target for cancer diagnosis and therapy
WO2008134752A3 (en) Methods and compositions for the treatment of cancer
WO2011005570A3 (en) Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer
EP2195425A4 (en) Pkib and naaladl2 for target genes of prostate cancer therapy and diagnosis
WO2009126315A3 (en) Macrocyclic compounds and methods of treatment
WO2008121467A3 (en) Combination therapy for treating cancer

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08742077

Country of ref document: EP

Kind code of ref document: A2